PharmaFocus Today – Page 28 – media

Eli Lilly’s new drug Inluriyo has been approved by the US FDA for the treatment of advanced or metastatic breast cancer

Recently, Eli Lillyannounced that the U.S. Food and Drug Administration (FDA) has approved its oral estrogen receptor antagonist Inluriyo (imlunestrant, 200 mg tablets) for the treatment of adult patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-), ESR1-mutated advanced or metastatic breast cancer (MBC) whose disease has progressed after at least one line of endocrine therapy (ET). https://finance.eastmoney.com/a/202509283525492454.html
- Source: drugdu
- 99
- September 29, 2025
New specifications of sitagliptin and metformin extended-release tablets approved

　　Xuantai PharmaceuticalOn September 26, the company announced that its wholly-owned subsidiary, Jiangsu Xuantai Pharmaceutical Co., Ltd., received the “Notice of Approval of Supplementary Drug Application” from the National Medical Products Administration (NMPA). The NMPA approved the company’s supplemental application for sitagliptin and metformin extended-release tablets to include 50 mg of sitagliptin phosphate (calculated as CHFNO3) and 500 mg of metformin hydrochloride per tablet. Currently marketed, the dosage form contains 50 mg of sitagliptin phosphate (calculated as CHFNO3) and 1000 mg of metformin hydrochloride per tablet. This newly approved dosage form will help better meet patient needs, enhance product competitiveness and market share, and positively impact the company’s future performance. https://finance.eastmoney.com/a/202509263524765181.html
- Source: drugdu
- 84
- September 29, 2025
Based on the logic of prosperity and industry trends, public fundraising explores advantages, styles, and opportunities for “diffusion”

Since the Federal Reserve cut interest rates in September, the technology growth style of the A-share market has continued to strengthen. As of September 26th, several semiconductor equipment related themed ETFs have performed well. Industry institutions analyze that new developments in the artificial intelligence (AI) industry are constantly emerging, and the structural market driven by growth styles is still ongoing. However, with the “pre holiday effect” of the National Day holiday, if there is no significant positive catalyst, the market may be mainly volatile in the near future. At the same time as the valuation of the technology sector enters a high level, the internal rotation of the sector is also accelerating. Industry institutions suggest that the previous extreme structural differentiation and overly concentrated consensus in the market need to be digested and consolidated. In the current market driven by incremental funds and the prosperity of some industries, rotation is ...
- Source: drugdu
- 98
- September 29, 2025
Guangzhou Pharmaceutical Baiyunshan’s fund plans to invest 749 million yuan to become the second largest shareholder of Nanjing Pharmaceutical

On the evening of September 28th, Baiyunshan, a listed company under Guangzhou Pharmaceutical Group, and Nanjing Pharmaceutical Co., Ltd. (hereinafter referred to as “Nanjing Pharmaceutical”) announced that Baiyunshan’s Guangzhou Pharmaceutical Phase II Fund Equity Investment Partnership Enterprise (Limited Partnership) (hereinafter referred to as “Guangzhou Pharmaceutical Phase II Fund”) plans to invest 749 million yuan to acquire 145 million non restricted shares of Nanjing Pharmaceutical held by Alliance Healthcare Asia Pacific Limited (“AHAPL”), accounting for 11.04% of the total shares of Nanjing Pharmaceutical. After the acquisition is completed, Guangzhou Pharmaceutical Phase II Fund will become the second largest shareholder of Nanjing Pharmaceutical. According to the announcement, on September 26th, Guangzhou Pharmaceutical Phase II Fund signed a share transfer contract with AHAPL. The buyer and seller agreed to use the arithmetic mean of the daily closing prices of the target company for the 60 trading days prior to the signing date ...
- Source: drugdu
- 132
- September 29, 2025
Fathers who smoked as teens may accelerate their children’s biological aging

People whose fathers smoked during puberty seem to age faster than expected, according to research presented at the European Respiratory Society (ERS) Congress in Amsterdam, the Netherlands. The researchers found signs of faster biological ageing, compared to chronological age, in people whose fathers began smoking at age 15 or younger. They say smoking during puberty may create damage in boys’ developing sperm cells that can be passed on to their children. The researchers call for stronger efforts to prevent tobacco use in teenagers, not only to benefit the current generation but also future generations. The study was presented by Dr Juan Pablo López-Cervantes from the University of Bergen, Norway. He said: “Our research group has previously shown that smoking during puberty may harm not only the person who smokes, but also their future children. In this new study, we wanted to explore whether parental smoking in puberty may also influence ...
- Source: drugdu
- 76
- September 29, 2025
Remote asthma monitoring keeps children out of the emergency department

Children with asthma who use at-home monitoring are around half as likely to visit the emergency department or be hospitalized, compared to those who only receive care from their medical team, according to research presented at the European Respiratory Society (ERS) Congress in Amsterdam, the Netherlands. Remote monitoring also helped keep children’s symptoms under control. At-home monitoring involved children and their families using an app approximately once a month to answer questions about asthma symptoms or track their lung function. The app also contains asthma action and treatment plans, and information on prescribed medications and instructions on how to use them. At-home monitoring is used to reduce in-person outpatient visits when children have stable asthma symptoms. The research was presented by Dr Martinus Oppelaar from Amalia Children’s Hospital, Radboud University Center, Nijmegen, the Netherlands. He told the Congress: “Our team has previously run a successful clinical trial where we showed ...
- Source: drugdu
- 94
- September 29, 2025
Gene Therapy Slows Huntington’s Disease in Early Trial

FRIDAY, Sept. 26, 2025 (HealthDay News) — A new gene therapy has shown promise in slowing the progression of Huntington’s disease, according to early trial results released Wednesday. In a Phase 1/2 study, patients given a high dose of UniQure’s experimental therapy AMT-130 experienced a 75% slowing of disease progression after three years, the company said. The therapy also reduced levels of a key marker of brain damage — neurofilament light protein in spinal fluid — by an average of 8.2%. “These findings reinforce our conviction that AMT-130 has the potential to fundamentally transform the treatment landscape for Huntington’s disease,” Dr. Walid Abi-Saab, chief medical officer at UniQure, told CNN. The trial, run in partnership with University College London, included 29 patients treated with either a high or low dose of AMT-130 and followed for 36 months. The treatment was delivered surgically by injecting the therapy directly into the brain’s ...
- Source: drugdu
- 90
- September 28, 2025
Regeneron’s Evkeeza Approved in U.S. for Young Children with Homozygous Familial Hypercholesterolemia

Regeneron announced FDA’s approval of its ANGPTL3 antibody Evkeeza for treatment of homozygous familial hypercholesterolemia (HoFH) in children ages 1 to less than 5-years-old. Evkeeza was initially approved in 2021 for use in adults and children aged 12-and-up, and received approval again in 2023 for use in children aged 5 to 11-years-old. Each of Evkeeza’s approvals were reviewed under Priority Review, a process which is reserved for medications representing potential improvements in either efficiency or safety of treating serious diseases. “The approval of Evkeeza for children as young as 1 year of age addresses a critical unmet need for those with homozygous familial hypercholesterolemia, a life-threatening condition that causes extraordinarily high LDL-C levels from birth,” said Katherine Wilemon, founder and CEO of the Family Heart Foundation. “Families and their medical teams will now have an effective treatment option for these very young children who are at risk of serious complications ...
- Source: drugdu
- 83
- September 28, 2025
There are as many as 330 million cardiovascular patients in China, and we need to be alert to the risk of comorbidities

Currently, the number of cardiovascular disease patients in China is as high as 330 million, including 245 million patients with hypertension and over 10 million patients with coronary heart disease and stroke; Cardiovascular diseases account for nearly 50% of total deaths among residents, ranking first among all types of diseases and being known as the “number one killer” that threatens residents’ health. With the deepening of the “Healthy China 2030” strategy, the prevention and control of cardiovascular and cerebrovascular diseases have been included in the key prevention and control category, and the results have been significant. However, in the context of accelerated aging, the overall prevention and control situation is still grim: on the one hand, the number of cardiovascular disease patients is huge, and the incidence rate continues to rise; On the other hand, middle-aged and elderly patients often face the problem of multiple diseases coexisting, and the “interweaving ...
- Source: drugdu
- 83
- September 28, 2025
The National Healthcare Security Administration has issued 33 batches of project initiation guidelines; Borui Pharmaceutical’s IPO in Hong Kong

The National Medical Insurance Administration carries out the third national video dispatch for the special rectification of prominent issues in the management of medical insurance funds On the morning of September 26th, the National Medical Insurance Administration launched the third national video dispatch of the special rectification work on prominent issues in the management of medical insurance funds, summarizing the progress and effectiveness of the special rectification in the previous stage, and making arrangements for the implementation of the “100 day action”. Deployment requirements: This “100 day action” should focus on prominent illegal and irregular issues in the medical insurance field, closely monitor the three key tasks of reselling medical insurance return drugs, illegally prescribing excessive drugs, and defrauding maternity allowances, carry out concentrated and precise rectification, strictly investigate and crack down in accordance with laws and regulations, and strive to basically eliminate the problem of reselling medical insurance return ...
- Source: drugdu
- 127
- September 28, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.